Navigation Links
NeoStem's CEO Letter to Shareholders
Date:1/3/2012

NEW YORK, Jan. 3, 2012 /PRNewswire/ --

Dear NeoStem Shareholders,

We would like to take a moment to both look back at 2011 - a transformative year for NeoStem (NYSE Amex: NBS) – and to look ahead to near term catalysts that we expect to move the company forward in 2012 and beyond.

  • We have closed two acquisitions - Progenitor Cell Therapy, LLC ("PCT") and Amorcyte, LLC ("Amorcyte").
  • We believe our therapeutic product development team is very close to accomplishing its aggressive goal of getting a first patient enrolled in our AMR-001 Phase 2 clinical trial for the treatment of AMI with the clinical sites beginning to open.  This brings us closer to achieving our goal of enrollment of the targeted 160 patients in the study over the next year or so with first data follow-up six months after the last patient is enrolled (roughly mid-2013).
  • Our cell therapy manufacturing business is growing and client satisfaction confirms our belief and excitement that we have unique skills and people (expertise, quality and work ethic) to serve as a platform to be a global leader in the cell therapy space.
  • We raised $16.5 million in gross proceeds in 2011 for working capital, including research and development of our cell therapeutic candidates.
  • We received awards of over $1.7 million in Department of Defense funding for development of our VSELTM Technology to treat osteoporosis and $245,176 from the National Institutes of Health (NIH) with Excell Therapeutics to progress our T regulatory program in Lupus. 
  • We co-hosted a spectacular international conference in partnership with the Vatican's Pontifical Council for Culture on Adult Stem Cells: Science and the Future of Man and Culture, moving forward the public discussion of adult stem cells and adult stem cell research.
  • Our cord blood banking
    '/>"/>

  • SOURCE NeoStem, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
    2. CTI Receives NASDAQ Letter
    3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
    4. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
    5. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
    6. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
    7. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
    8. Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter
    9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
    10. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
    11. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... ... 2015 , ... Proove Biosciences , a commercial and ... Intervention Society’ s 23rd Annual Scientific Meeting (ASM). The ASM event took ... on evidence-based research and clinical application, the event gathered industry thought leaders to ...
    (Date:8/28/2015)... ... 28, 2015 , ... Riordan-McKenna Institute founders, stem ... that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic ... surgical knee wound. , The case involved a 78-year-old male, who presented with ...
    (Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , ... problems, is pleased to announce their ranking as one of the top 5000 companies ... fastest-growing private companies across the nation. , “It is truly an honor to be ...
    (Date:8/27/2015)... Aug. 27, 2015 The National Necrotizing ... eyes—and life—were saved by doctors at Vanderbilt University Hospital ... NNFF, NovaBay Pharmaceuticals and Dr. John Crew , ... at Seton Medical Center in Daly City, ... a breakthrough approach, pioneered by Dr. Crew, that had ...
    Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
    ... FOLD ) today announced that it will host an ... PM at the Four Seasons Hotel in New,York City. The ... 2 clinical trials performed for Amigal(TM) (migalastat hydrochloride),for Fabry disease ... and development programs at the company., A live audio ...
    ... (Pre-Market Notification), Pathway for AppyScore(TM), the First Blood-based Screening and Triage ... ... 27 AspenBio Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical ... and humans, has,received an official response from the Food and Drug ...
    ... Israel, Nov. 27 Shamir,Optical Industry Ltd. (Nasdaq: ... technology to the progressive ophthalmic lens,market, today announced unaudited ... For the quarter ended September 30, 2007, revenues ... for the third quarter of 2006.,Gross profit for the ...
    Cached Biology Technology:Amicus Therapeutics to Host R&D Day 2Amicus Therapeutics to Host R&D Day 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 2Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 3Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 5Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 6Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 7Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 8Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 9Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 10
    (Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
    (Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
    (Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
    Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
    ... Network and University of Toronto have identified a small ... with chronic Hepatitis C will be able to respond ... the basis of a simple new test in the ... , The study, published in the May issue of ...
    ... new research tool will allow University of Oregon scientists ... their quest to test and understand the human body's ... environmental chamber, is a 12-foot-square room capable of simulating ... a set point between 14 and 122 degrees Fahrenheit, ...
    ... stem cells can develop in the laboratory into the early ... work opens up the possibility that eggs and sperm could ... therapeutic cloning and the creation of more stem cells for ... from a range of diseases. , Behrouz Aflatoonian will tell ...
    Cached Biology News:Identification of specific genes predicts which patients will respond to Hepatitis C treatment 2Identification of specific genes predicts which patients will respond to Hepatitis C treatment 3Going To Extremes To Improve Human Health 2Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 2Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory 3
    ... includes 2 tube gel adaptors, 24 ... length), gaskets, grommets, stoppers. The PROTEAN II ... cell offer the versatility to perform a ... second-dimension 2-D electrophoresis, native, preparative, and gradient ...
    StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
    ... The PROTEAN II XL cell, wide format, is used ... x 20 cm gels and requires 1.2 L of ... unit and the 2.0 mm IPG conversion kit, which ... and includes 2 sets of IPG clamps, 2 sets ...
    ... depletion cocktail is tailored to ... suspensions of rat spleen cells. ... StemSep (or compatible 0.5 Tesla) ... T cell content of the ...
    Biology Products: